

www.nephro-pathology.com

LITERATURE GUIDE

VOLUME 5

DENSE DEPOSIT DISEASE

Nasr SH, Valeri AM, Appel GB et. al. [Dense Deposit Disease: Clinicopathologic Study of 32 Pediatric and Adult Patients.](#)

CJASN 2009; 4(1): 22-32. (Full text)

Maria Asuncion Abrera-Abeleda, Carla Nishimura, Kathy Frees et. al. [Allelic Variants of Complement Genes Associated with Dense Deposit Disease.](#) J Am Soc Nephrol. 2011 August; 22(8): 1551–1559. (Full text)

Abrera-Abeleda MA, Nishimura C, Smith JL et. al. [Variations in the complement regulatory genes factor H \(CFH\) and factor H related 5 \(CFHR5\) are associated with membranoproliferative glomerulonephritis type II \(dense deposit disease\).](#) J Med Genet. 2006 Jul;43(7):582-9. (Full text)

Hocking HG, Herbert AP, Kavanagh D et. al. [Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations.](#) J Biol Chem. 2008 Apr 4;283(14):9475-87. (Full text)

Schmidt CQ, Herbert AP, Hocking HG et. al. [Translational mini-review series on complement factor H: structural and functional correlations for factor H.](#) Clin Exp Immunol. 2008 Jan;151(1):14-24. (Full text)

Pechtl IC, Kavanagh D, McIntosh et. al. [Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.](#) J Biol Chem 2011 Apr 1;286(13):11082-90. (Full text)

Sethi S, Gamez JD, Vrana JA et. al. [Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.](#) Kidney Int. 2009 May;75(9):952-60. (Full text)

Martínez-Barricarte R, Heurich M, Valdes-Cañedo F et. al. [Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.](#) J Clin Invest. 2010 Oct;120(10):3702-12. (Full text)

Sethi S, Fervenza FC, Zhang Y et. al. [Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.](#) Clin J Am Soc Nephrol. 2011 May;6(5):1009-17. (Full text)

Vivarelli M, Pasini A, Emma F. [Eculizumab for the Treatment of Dense-Deposit Disease](#). *N Engl J Med* 2012; 366:1163-1165. (Full text)

Vernon KA, Pickering MC, Cook T. [Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease](#). *Contrib Nephrol*. 2011;169:198-210.

Herlitz LC, Bomback AS, Markowitz GS et. al. [Pathology after Eculizumab in Dense Deposit Disease and C3 GN](#). *J Am Soc Nephrol*. 2012 Jun 7. [Epub ahead of print]

Servais A, Noël LH, Roumenina LT, Le Quintrec M et. al. [Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies](#). *Kidney Int*. 2012 Mar 28. [Epub ahead of print].

Zhang Y, Meyer NC, Wang k et. al. [Causes of alternative pathway dysregulation in dense deposit disease](#). *Clin J Am Soc Nephrol*. 2012 Feb;7(2):265-74.

Sethi S, Nester CM, Smith RJ. [Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion](#). *Kidney Int*. 2012 Mar;81(5):434-41.

Lu DF, Moon M, Lanning LD et. al. [Clinical features and outcomes of 98 children and adults with dense deposit disease](#). *Pediatr Nephrol*. 2012 May;27(5):773-81.

Sethi S, Fervenza FC. [Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification](#). *Semin Nephrol*. 2011 Jul;31(4):341-8.

Smith RJ, Harris CL, Pickering MC. [Dense deposit disease](#). *Mol Immunol*. 2011 Aug;48(14):1604-10.